Synthesis and structure-activity relationships for extended side chain analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).

@article{Palmer2015SynthesisAS,
  title={Synthesis and structure-activity relationships for extended side chain analogues of the antitubercular drug (6S)-2-nitro-6-\{[4-(trifluoromethoxy)benzyl]oxy\}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).},
  author={Brian D. Palmer and Hamish S. Sutherland and Adrian Blaser and Iveta Kmentova and Scott G Franzblau and Baojie Wan and Yuehong Wang and Zhenkun Ma and William A. Denny and Andrew M Thompson},
  journal={Journal of medicinal chemistry},
  year={2015},
  volume={58 7},
  pages={3036-59}
}
Novel extended side chain nitroimidazooxazine analogues featuring diverse linker groups between two aryl rings were studied as a potential strategy to improve solubility and oral activity against chronic infection by Mycobacterium tuberculosis. Both lipophilic and highly polar functionalities (e.g., carboxamide, alkylamine, piperazine, piperidine, but not… CONTINUE READING